HR | 95%CI | p | |
---|---|---|---|
Age | |||
< 50 | |||
≥ 50 | 1.4 | 0.84–2.3 | 0.2 |
VD level | |||
< 20 ng/mL | |||
≥ 20 ng/mL | 0.9 | 0.6–1.5 | 0.8 |
Clinical stage | |||
I-II | |||
III | 2.4 | 1.4–3.9 | 0.001 |
Tumor subtypes | |||
HER2+ | 1.6 | 0.30–1.21 | 0.2 |
HR+/HER2- | |||
TNBC | 4.3 | 1.42–4.80 | 0.002 |
pCR | |||
no | |||
yes | 0.25 | 0.12–0.50 | 0.0001 |
SBR grade | |||
II | |||
III | 0.94 | 0.52–1.70 | 0.8 |